

TDMS No. 20209 - 02
Test Type: 90-DAY
Route: GAVAGE
Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Reqsted: 10/16/2007
Time Report Reqsted: 14:58:05
First Dose M/F: 07/21/04 / 07/22/04
Lab: SRI

F1_M3

C Number: C20209
Lock Date: 12/07/2005
Cage Range: ALL
Date Range: ALL
Reasons For Removal: ALL
Removal Date Range: ALL
Treatment Groups: Include ALL
TDMSE Version: 1.8.0

TDMS No. 20209 - 02

Test Type: 90-DAY

Route: GAVAGE

Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS

Pentabromodiphenyl oxide (technical) (DE 71)

CAS Number: 32534-81-9

Date Report Requested: 10/16/2007

Time Report Requested: 14:58:05

First Dose M/F: 07/21/04 / 07/22/04

Lab: SRI

SUMMARY OF STATISTICALLY SIGNIFICANT (P<=.05) RESULTS IN THE ANALYSIS OF Pentabromodiphenyl oxide (technical) (DE 71)

MALE MICE

Organ

Adrenal Cortex
Adrenal Cortex: Zona Fasciculata
Esophagus
Liver
Liver: Hepatocyte

Spleen: Lymphoid Follicle
Stomach, Glandular
Testes
Thymus

FEMALE MICE

Organ

Adrenal Cortex
Liver: Hepatocyte

Pleura
Stomach, Forestomach: Epithelium
Stomach, Glandular
Thymus

Morphology

Degeneration Fatty
Hypertrophy
Inflammation
Necrosis Focal
Hypertrophy
Necrosis
Vacuolization Cytoplasmic
Atrophy
Erosion
Abnormal Residual Body
Atrophy

Morphology

Degeneration Fatty
Hypertrophy
Necrosis
Inflammation
Hyperplasia
Erosion
Atrophy

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Adrenal Cortex
 Degeneration Fatty**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	4/10 (40%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.00	0/10.00	0/10.00	4/7.43
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	53.8%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	---	---	---	26

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.025*
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.009**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.012*
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.007**
LOGISTIC REGRESSION	P=0.070	(e)	(e)	(e)	(e)	P=0.355
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.043*
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Adrenal Cortex: Zona Fasciculata
 Hypertrophy**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.00	0/10.00	0/10.00	5/8.61
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	58.1%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	---	---	---	26

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.015*
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P=0.003**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P=0.004**
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P=0.002**
LOGISTIC REGRESSION	P=0.549	(e)	(e)	(e)	(e)	P=0.793
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.016*
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Esophagus
 Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	5/10.00	0/10.00	2/5.32
POLY-3 PERCENT (g)	0%	0%	0%	50%	0%	37.6%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	5/10 (50%)	0/10 (0%)	1/3 (33%)
FIRST INCIDENCE	---	---	---	93 (T)	---	34

STATISTICAL TESTS

LIFE TABLE	P=0.024*	(e)	(e)	P=0.022*	(e)	P=0.093
POLY 3	P=0.057	(e)	(e)	P=0.008**	(e)	P=0.107
POLY 1.5	P=0.087	(e)	(e)	P=0.008**	(e)	P=0.133
POLY 6	P=0.041*	(e)	(e)	P=0.008**	(e)	P=0.090
LOGISTIC REGRESSION	P=0.341	(e)	(e)	P=0.022*	(e)	P=0.346
COCH-ARM / FISHERS	P=0.260	(e)	(e)	P=0.016*	(e)	P=0.237
ORDER RESTRICTED	P=0.027*	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.088	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	2/5.50
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	36.4%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	---	---	---	59

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.102
POLY 3	P=0.003**	(e)	(e)	(e)	(e)	P=0.112
POLY 1.5	P=0.004**	(e)	(e)	(e)	(e)	P=0.132
POLY 6	P=0.003**	(e)	(e)	(e)	(e)	P=0.104
LOGISTIC REGRESSION	P=0.024*	(e)	(e)	(e)	(e)	P=0.258
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.006**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Hypertrophy

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	10/10 (100%)	10/10 (100%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	10/10.00	10/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	10%	100%	100%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	10/10 (100%)	10/10 (100%)	3/3 (100%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	93 (T)	26

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 3	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
LOGISTIC REGRESSION	(e)	(e)	P=0.500	P<0.001**	P<0.001**	(e)
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	P<0.001**	P<0.001**	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Necrosis

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	10/10 (100%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	1/10.00	10/10.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	10%	100%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	3/3 (100%)
FIRST INCIDENCE	---	---	---	---	93 (T)	26

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	P=0.500	P<0.001**
POLY 3	P<0.001**	(e)	(e)	(e)	P=0.500	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P=0.500	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P=0.500	P<0.001**
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	P=0.500	(e)
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P=0.500	P<0.001**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	6/10 (60%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	6/6.14
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	97.7%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	3/3 (100%)
FIRST INCIDENCE	---	---	---	---	---	59

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.005**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Lung
 Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	1/10.00	1/10.00	0/10.00	0/10.00	1/4.37
POLY-3 PERCENT (g)	0%	10%	10%	0%	0%	22.9%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	1/3 (33%)
FIRST INCIDENCE	---	93 (T)	93 (T)	---	---	93 (T)

STATISTICAL TESTS

LIFE TABLE	P=0.249	P=0.500	P=0.500	(e)	(e)	P=0.261
POLY 3	P=0.415	P=0.500	P=0.500	(e)	(e)	P=0.352
POLY 1.5	P=0.433	P=0.500	P=0.500	(e)	(e)	P=0.391
POLY 6	P=0.409	P=0.500	P=0.500	(e)	(e)	P=0.327
LOGISTIC REGRESSION	(e)	P=0.500	P=0.500	(e)	(e)	P=0.261
COCH-ARM / FISHERS	P=0.530	P=0.500	P=0.500	(e)	(e)	P=0.500
ORDER RESTRICTED	P=0.163	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.290	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Pleura
 Inflammation**

LESION RATES

OVERALL (a)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
POLY-3 RATE (b)	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00	0/0.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Spleen: Lymphoid Follicle
 Atrophy**

LESION RATES

OVERALL (a)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	3/10 (30%)
POLY-3 RATE (b)	0/10.00	1/10.00	1/10.00	0/10.00	0/10.00	3/7.04
POLY-3 PERCENT (g)	0%	10%	10%	0%	0%	42.6%
TERMINAL (d)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	93 (T)	93 (T)	---	---	26

STATISTICAL TESTS

LIFE TABLE	P=0.003**	P=0.500	P=0.500	(e)	(e)	P=0.084
POLY 3	P=0.011*	P=0.500	P=0.500	(e)	(e)	P=0.041*
POLY 1.5	P=0.013*	P=0.500	P=0.500	(e)	(e)	P=0.052
POLY 6	P=0.010**	P=0.500	P=0.500	(e)	(e)	P=0.033*
LOGISTIC REGRESSION	P=0.783N	P=0.500	P=0.500	(e)	(e)	P=0.838
COCH-ARM / FISHERS	P=0.023*	P=0.500	P=0.500	(e)	(e)	P=0.105
ORDER RESTRICTED	P=0.002**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.010**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	1/10.00	0/10.00	1/4.75
POLY-3 PERCENT (g)	0%	0%	10%	10%	0%	21%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	1/10 (10%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	93 (T)	93 (T)	---	79

STATISTICAL TESTS

LIFE TABLE	P=0.199	(e)	P=0.500	P=0.500	(e)	P=0.318
POLY 3	P=0.306	(e)	P=0.500	P=0.500	(e)	P=0.364
POLY 1.5	P=0.340	(e)	P=0.500	P=0.500	(e)	P=0.397
POLY 6	P=0.289	(e)	P=0.500	P=0.500	(e)	P=0.347
LOGISTIC REGRESSION	P=0.412	(e)	P=0.500	P=0.500	(e)	P=0.468
COCH-ARM / FISHERS	P=0.464	(e)	P=0.500	P=0.500	(e)	P=0.500
ORDER RESTRICTED	P=0.169	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.291	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/9 (22%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/10.00	0/10.00	0/10.00	2/5.47
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	36.5%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	---	---	---	59

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.102
POLY 3	P=0.002**	(e)	(e)	(e)	(e)	P=0.107
POLY 1.5	P=0.002**	(e)	(e)	(e)	(e)	P=0.125
POLY 6	P=0.002**	(e)	(e)	(e)	(e)	P=0.099
LOGISTIC REGRESSION	P=0.029*	(e)	(e)	(e)	(e)	P=0.273
COCH-ARM / FISHERS	P=0.007**	(e)	(e)	(e)	(e)	P=0.211
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.004**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Testes
 Abnormal Residual Body

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	1/10 (10%)	5/10 (50%)
POLY-3 RATE (b)	0/10.00	0/10.00	1/10.00	0/10.00	1/10.00	5/5.70
POLY-3 PERCENT (g)	0%	0%	10%	0%	10%	87.7%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/10 (0%)	1/10 (10%)	3/3 (100%)
FIRST INCIDENCE	---	---	93 (T)	---	93 (T)	34

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	P=0.500	(e)	P=0.500	P<0.001**
POLY 3	P<0.001**	(e)	P=0.500	(e)	P=0.500	P<0.001**
POLY 1.5	P<0.001**	(e)	P=0.500	(e)	P=0.500	P<0.001**
POLY 6	P<0.001**	(e)	P=0.500	(e)	P=0.500	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	P=0.500	(e)	P=0.500	P=0.002**
COCH-ARM / FISHERS	P<0.001**	(e)	P=0.500	(e)	P=0.500	P=0.016*
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Males					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	6/9 (67%)
POLY-3 RATE (b)	0/10.00	0/10.00	0/9.00	0/10.00	0/10.00	6/9.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	66.7%
TERMINAL (d)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/3 (0%)
FIRST INCIDENCE	---	---	---	---	---	26

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P=0.006**
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.003**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Adrenal Cortex
 Degeneration Fatty**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	2/7.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	28.6%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	32

STATISTICAL TESTS

LIFE TABLE	P=0.003**	(e)	(e)	(e)	(e)	P=0.171
POLY 3	P=0.004**	(e)	(e)	(e)	(e)	P=0.168
POLY 1.5	P=0.004**	(e)	(e)	(e)	(e)	P=0.169
POLY 6	P=0.004**	(e)	(e)	(e)	(e)	P=0.168
LOGISTIC REGRESSION	P=0.043*	(e)	(e)	(e)	(e)	P=0.283
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
ORDER RESTRICTED	P=0.002**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.008**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Adrenal Cortex: Zona Fasciculata
 Hypertrophy**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	0/5.65
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Esophagus
 Inflammation**

LESION RATES

OVERALL (a)	3/10 (30%)	0/10 (0%)	0/10 (0%)	7/10 (70%)	1/10 (10%)	3/10 (30%)
POLY-3 RATE (b)	3/10.00	0/10.00	0/10.00	7/10.00	1/10.00	3/6.65
POLY-3 PERCENT (g)	30%	0%	0%	70%	10%	45.1%
TERMINAL (d)	2/9 (22%)	0/10 (0%)	0/10 (0%)	6/9 (67%)	0/9 (0%)	2/5 (40%)
FIRST INCIDENCE	5	---	---	7	5	6

STATISTICAL TESTS

LIFE TABLE	P=0.119	P=0.108N	P=0.108N	P=0.127	P=0.303N	P=0.443
POLY 3	P=0.115	P=0.095N	P=0.095N	P=0.082	P=0.292N	P=0.461
POLY 1.5	P=0.132	P=0.095N	P=0.095N	P=0.082	P=0.292N	P=0.489
POLY 6	P=0.102	P=0.095N	P=0.095N	P=0.082	P=0.292N	P=0.437
LOGISTIC REGRESSION	P=0.558N	P=0.204N	P=0.204N	P=0.077	P=0.227N	P=0.615N
COCH-ARM / FISHERS	P=0.352	P=0.105N	P=0.105N	P=0.089	P=0.291N	P=0.686N
ORDER RESTRICTED	P=0.066	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.131	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver
 Necrosis Focal

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	0/5.65
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Hypertrophy

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	9/10 (90%)	6/10 (60%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	9/9.00	6/6.04
POLY-3 PERCENT (g)	0%	0%	0%	0%	100%	99.3%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	9/9 (100%)	5/5 (100%)
FIRST INCIDENCE	---	---	---	---	93 (T)	79

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 3	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	(e)	(e)	P<0.001**	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	P<0.001**	P=0.005**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Necrosis

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	6/10 (60%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	6/6.04
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	99.3%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	5/5 (100%)
FIRST INCIDENCE	---	---	---	---	---	79

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 3	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 1.5	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
POLY 6	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
LOGISTIC REGRESSION	P<0.001**	(e)	(e)	(e)	(e)	P<0.001**
COCH-ARM / FISHERS	P<0.001**	(e)	(e)	(e)	(e)	P=0.005**
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

Liver: Hepatocyte
 Vacuolization Cytoplasmic

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	0/5.65
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	---

STATISTICAL TESTS

LIFE TABLE	(e)	(e)	(e)	(e)	(e)	(e)
POLY 3	(e)	(e)	(e)	(e)	(e)	(e)
POLY 1.5	(e)	(e)	(e)	(e)	(e)	(e)
POLY 6	(e)	(e)	(e)	(e)	(e)	(e)
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	(e)	(e)	(e)	(e)	(e)	(e)
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Lung
 Inflammation**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	0/10 (0%)	0/10 (0%)
POLY-3 RATE (b)	0/9.00	0/10.00	1/10.00	2/10.00	0/9.00	0/5.65
POLY-3 PERCENT (g)	0%	0%	10%	20%	0%	0%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	1/10 (10%)	1/9 (11%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	93 (T)	7	---	---

STATISTICAL TESTS

LIFE TABLE	P=0.600N	(e)	P=0.521	P=0.251	(e)	(e)
POLY 3	P=0.568N	(e)	P=0.521	P=0.252	(e)	(e)
POLY 1.5	P=0.559N	(e)	P=0.521	P=0.252	(e)	(e)
POLY 6	P=0.575N	(e)	P=0.521	P=0.252	(e)	(e)
LOGISTIC REGRESSION	P=0.293N	(e)	P=0.522	P=0.200	(e)	(e)
COCH-ARM / FISHERS	P=0.470N	(e)	P=0.500	P=0.237	(e)	(e)
ORDER RESTRICTED	P=0.498	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.558	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Pleura
 Inflammation**

LESION RATES

OVERALL (a)	1/10 (10%)	0/10 (0%)	1/10 (10%)	2/10 (20%)	1/10 (10%)	3/10 (30%)
POLY-3 RATE (b)	1/10.00	0/10.00	1/10.00	2/10.00	1/10.00	3/8.65
POLY-3 PERCENT (g)	10%	0%	10%	20%	10%	34.7%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	1/10 (10%)	1/9 (11%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	5	---	93 (T)	7	5	4

STATISTICAL TESTS

LIFE TABLE	P=0.049*	P=0.500N	P=0.749N	P=0.512	P=0.766	P=0.276
POLY 3	P=0.066	P=0.500N	P=0.760	P=0.500	P=0.760	P=0.236
POLY 1.5	P=0.072	P=0.500N	P=0.760	P=0.500	P=0.760	P=0.250
POLY 6	P=0.062	P=0.500N	P=0.760	P=0.500	P=0.760	P=0.224
LOGISTIC REGRESSION	P=0.338N	(e)	P=0.522	P=0.250	(e)	(e)
COCH-ARM / FISHERS	P=0.089	P=0.500N	P=0.763N	P=0.500	P=0.763N	P=0.291
ORDER RESTRICTED	P=0.056	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.085	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Spleen: Lymphoid Follicle
 Atrophy**

LESION RATES

OVERALL (a)	1/10 (10%)	0/0 (0%)	0/0 (0%)	0/1 (0%)	1/10 (10%)	2/10 (20%)
POLY-3 RATE (b)	1/10.00	0/0.00	0/0.00	0/0.00	1/10.00	2/6.65
POLY-3 PERCENT (g)	10%	0%	0%	0%	10%	30.1%
TERMINAL (d)	0/9 (0%)	0/0 (0%)	0/0 (0%)	0/0 (0%)	0/9 (0%)	1/5 (20%)
FIRST INCIDENCE	5	---	---	---	5	4

STATISTICAL TESTS

LIFE TABLE	P=0.098	(e)	(e)	P=0.500N	P=0.766	P=0.408
POLY 3	(e)	(e)	(e)	P=0.943N	P=0.760	P=0.356
POLY 1.5	(e)	(e)	(e)	P=0.943N	P=0.760	P=0.374
POLY 6	(e)	(e)	(e)	P=0.943N	P=0.760	P=0.343
LOGISTIC REGRESSION	P=0.683	(e)	(e)	(e)	(e)	P=0.776N
COCH-ARM / FISHERS	P=0.383	(e)	(e)	P=0.909N	P=0.763N	P=0.500
ORDER RESTRICTED	(e)	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	(e)	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Stomach, Forestomach: Epithelium
 Hyperplasia**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	2/10 (20%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	2/7.00
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	28.6%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	32

STATISTICAL TESTS

LIFE TABLE	P=0.003**	(e)	(e)	(e)	(e)	P=0.171
POLY 3	P=0.004**	(e)	(e)	(e)	(e)	P=0.168
POLY 1.5	P=0.004**	(e)	(e)	(e)	(e)	P=0.169
POLY 6	P=0.004**	(e)	(e)	(e)	(e)	P=0.168
LOGISTIC REGRESSION	P=0.043*	(e)	(e)	(e)	(e)	P=0.283
COCH-ARM / FISHERS	P=0.010**	(e)	(e)	(e)	(e)	P=0.237
ORDER RESTRICTED	P=0.002**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.008**	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Stomach, Glandular
 Erosion**

LESION RATES

OVERALL (a)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	0/9.00	0/9.00	1/6.04
POLY-3 PERCENT (g)	0%	0%	0%	0%	0%	16.6%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	---	---	79

STATISTICAL TESTS

LIFE TABLE	P=0.079	(e)	(e)	(e)	(e)	P=0.419
POLY 3	P=0.101	(e)	(e)	(e)	(e)	P=0.422
POLY 1.5	P=0.103	(e)	(e)	(e)	(e)	P=0.427
POLY 6	P=0.101	(e)	(e)	(e)	(e)	P=0.421
LOGISTIC REGRESSION	P=0.139	(e)	(e)	(e)	(e)	P=0.468
COCH-ARM / FISHERS	P=0.140	(e)	(e)	(e)	(e)	P=0.500
ORDER RESTRICTED	P=0.029*	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P=0.073	(e)	(e)	(e)	(e)	(e)

TDMS No. 20209 - 02
 Test Type: 90-DAY
 Route: GAVAGE
 Species/Strain: MICE/B6C3F1

P10: STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS
 Pentabromodiphenyl oxide (technical) (DE 71)
 CAS Number: 32534-81-9

Date Report Requested: 10/16/2007
 Time Report Requested: 14:58:05
 First Dose M/F: 07/21/04 / 07/22/04
 Lab: SRI

**STATISTICAL ANALYSIS OF NON-NEOPLASTIC LESIONS IN MICE(B6C3F1)
 TERMINAL SACRIFICE AT 14 WEEKS**

DOSE	Females					
	0 MG/KG	0.01 MG/KG	5 MG/KG	50 MG/KG	100 MG/KG	500 MG/KG

**Thymus
 Atrophy**

LESION RATES

OVERALL (a)	0/9 (0%)	0/10 (0%)	0/10 (0%)	1/10 (10%)	0/9 (0%)	3/8 (38%)
POLY-3 RATE (b)	0/9.00	0/10.00	0/10.00	1/10.00	0/9.00	3/8.00
POLY-3 PERCENT (g)	0%	0%	0%	10%	0%	37.5%
TERMINAL (d)	0/9 (0%)	0/10 (0%)	0/10 (0%)	0/9 (0%)	0/9 (0%)	0/5 (0%)
FIRST INCIDENCE	---	---	---	7	---	4

STATISTICAL TESTS

LIFE TABLE	P<0.001**	(e)	(e)	P=0.521	(e)	P=0.082
POLY 3	P<0.001**	(e)	(e)	P=0.521	(e)	P=0.067
POLY 1.5	P<0.001**	(e)	(e)	P=0.521	(e)	P=0.067
POLY 6	P<0.001**	(e)	(e)	P=0.521	(e)	P=0.067
LOGISTIC REGRESSION	(e)	(e)	(e)	(e)	(e)	(e)
COCH-ARM / FISHERS	P=0.002**	(e)	(e)	P=0.526	(e)	P=0.082
ORDER RESTRICTED	P<0.001**	(e)	(e)	(e)	(e)	(e)
MAX-ISO-POLY-3	P<0.001**	(e)	(e)	(e)	(e)	(e)

LEGEND

- (a) Number of tumor-bearing animals/number of animals examined at site.
 - (b) Number of tumor-bearing animals/Poly-3 number
 - (d) Observed incidence at terminal kill.
 - (f) Beneath the control incidence are the P-values associated with the trend test. Beneath the dosed group incidence are the P-values corresponding to pairwise comparisons between the controls and that dosed group. The life table analysis regards tumors in animals dying prior to terminal kill as being (directly or indirectly) the cause of death.
 - (e) Value of Statistic cannot be computed.
 - (g) Poly-3 adjusted lifetime tumor incidence.
 - (I) Interim sacrifice
 - (T) Terminal sacrifice
 - # Tumor rates based on numbers of animals necropsied.
 - * To the right of any statistical result, indicates significance at ($P \leq 0.05$).
 - ** To the right of any statistical result, indicates significance at ($P \leq 0.01$).
 - N Indicates a negative trend for all tests
- Logistic regression is an alternative method for analyzing the incidence of non-fatal tumors.
The Cochran-Armitage and Fishers exact tests compare directly the overall incidence rates.

*** END OF REPORT ***